Maimaris, Jesmeen http://orcid.org/0000-0003-4169-8209
O’Sullivan, Anjel http://orcid.org/0000-0003-1207-3381
Underhill, Isabella http://orcid.org/0000-0002-2653-8285
Green, Ghiselle http://orcid.org/0000-0001-8607-7495
Symes, Andrew http://orcid.org/0000-0003-2223-7909
Lowe, David http://orcid.org/0000-0001-6102-2375
Burns, Siobhan http://orcid.org/0000-0002-3356-9506
Campbell, Mari http://orcid.org/0000-0001-5009-8307
Elfeky, Reem http://orcid.org/0000-0001-9382-150X
Article History
Received: 28 November 2022
Accepted: 7 June 2023
First Online: 26 June 2023
Declarations
:
: Not applicable.
: Not applicable.
: Not applicable.
: SOB has received grant support from CSL Behring and personal fees or travel expenses from Immunodeficiency Canada/IAACI, CSL Behring, Baxalta US Inc and Biotest. DML has received: research grants to his institution from LifeArc, Blood Cancer UK, Bristol Myers Squibb, GSK, British Society of Antimicrobial Chemotherapy, National Institute of Health Research and the UK Medical Research Council; speaker fees from Langland, Biotest and Gilead (educational video); travel, accommodation and conference fees from Octapharma; personal fees for a round-table discussion from Merck; and consultancy fees (to institution) from GSK. The rest of the authors declare that they have no conflicts of interest.